Parkinson?¦s disease (PD) is a devastating and an intricate complex neurological disorder that results from the progressive degeneration of nerve cells in Substantia nigra that controls movement. The pathological hallmark of PD is the formation of insoluble protein aggregates known as lewey bodies. Alpha-synuclein is the major constituent of these fibrillar structures. Alpha-synuclein a 140 ami...

Human ?-synuclein is a 140 amino acid protein with little or no secondary structure. The ?-synuclein is expressed at high levels in the brain and enriched in neural synaptic terminals but its physiological function remains largely unknown. More recently, ?-synuclein has been shown to be one of the principal componets of Lewy bodies, neuronal inclusions that are found in diverse human neurodegen...

Human ?-synuclein is a 140 amino acid protein with little or no secondary structure. The ?-synuclein is expressed at high levels in the brain and enriched in neural synaptic terminals but its physiological function remains largely unknown. More recently, ?-synuclein has been shown to be one of the principal componets of Lewy bodies, neuronal inclusions that are found in diverse human neurodegen...

Parkinson?¦s disease (PD) is a devastating and an intricate complex neurological disorder that results from the progressive degeneration of nerve cells in Substantia nigra that controls movement. The pathological hallmark of PD is the formation of insoluble protein aggregates known as lewey bodies. Alpha-synuclein is the major constituent of these fibrillar structures. Alpha-synuclein a 140 ami...

Background: Many of neurodegenerative diseases (NDs) are associated with formation of the protein aggregates called amyloidal fibrils. Fibrillization of alpha-synuclein seems to be a key stage in the creation and progression of NDs and finding the compounds that inhibit the toxicity of alpha-synuclein aggregates seems to be one of the most attention subjects in the neurodegenerative studies. ...

Background:Alpha-synuclein is a member of synuclein family of proteins with unidentified function localized in the cytoplasm, mitochondria of neurons, and presynaptic nerve endings. Although it is found in the Lewy bodies in synucleinopathies and in Alzheimer’s disease, the protein could also be considered as a novel marker in diagnosis of dis...

objective: alpha-synuclein is a major component of protein plaques in synucleinopathies, particularly parkinson’s disease. the purpose of this study is to assess the inhibitory effects of cuminaldehyde on the fibrillation of alpha-synuclein. methods: alpha-synuclein was expressed in escherichia coli and subsequently purified. for the process of fibrillation, purified protein was incubated at 3...

background:alpha-synuclein is a member of synuclein family of proteins with unidentified function localized in the cytoplasm, mitochondria of neurons, and presynaptic nerve endings. although it is found in the lewy bodies in synucleinopathies and in alzheimer’s disease, the protein could also be considered as a novel marker in diagnosis of diseases related to the hematopoietic system. methods: ...

?-Synuclein aggregation is a hallmark of Parkinson's disease and promising biomarker for early detection assessment progression. The prospect molecular test materializing with the recent developments methods based on amplification synuclein seeds (e.g. RT-QuIC or PMCA). Here we adapted single-molecule counting ?-synuclein aggregates in cerebrospinal fluid (CSF), using simple 3D printed microsco...

α-Synuclein is a key driver of the pathogenesis Parkinson disease (PD). Heme oxygenase-1 (HO-1), stress protein that catalyzes conversion heme to biliverdin, carbon monoxide and free ferrous iron, elevated in PD-affected neural tissues promotes iron deposition mitochondrial dysfunction models disease, pathways also impacted by α-synuclein. Elevated expression human HO-1 astrocytes GFAP.HMOX1 tr...